Equine CXCL6 (C-X-C motif chemokine ligand 6), also known as GCP-2 (granulocyte chemotactic protein 2), is a proinflammatory chemokine belonging to the ELR⁺ CXC chemokine family, which includes CXCL1, CXCL2, CXCL3, and CXCL5 that regulate neutrophil recruitment during inflammatory responses. In horses (Equus caballus), CXCL6 is produced by macrophages, epithelial cells, endothelial cells, and fibroblasts in response to proinflammatory cytokines such as IL-1β and TNF-α, microbial infection, or tissue injury. CXCL6 primarily signals through the chemokine receptor CXCR2, which is expressed on neutrophils and other innate immune cells, promoting chemotaxis, activation, and migration of neutrophils to sites of infection or inflammation. In equine health, CXCL6 contributes to innate immune responses in tissues such as the respiratory tract and skin, where neutrophil recruitment is important for controlling infections. CXCL6-mediated neutrophil trafficking is particularly relevant in equine respiratory diseases, including equine influenza and inflammatory airway disease, where chemokine-driven neutrophil accumulation influences airway inflammation, host defense, and disease severity. Consequently, equine CXCL6 is studied in veterinary immunology and respiratory disease research to better understand neutrophil-mediated inflammatory responses and host–pathogen interactions in horses.